# Ersel

> Ersel is a VC fund in Turin backing Biopharma, Life Science and Therapeutics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Turin, Italy
- Total investments: 2
- Last investment: Dec 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ersel
- X (Twitter): https://twitter.com/GruppoErsel/
- Website: https://www.ersel.it

Ersel is a VC fund in Turin focused on Biopharma and Life Science. Ersel provides the skills and experience of teams that deal with asset management, advisory services, corporate finance, and the setting-up of SICAVs and luxembourg funds. They offer its services for private customers and companies, institutional customers like banks, foundations, closed-end funds, asset management companies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 50% |
| Life Science | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ALKemist Bio | ALKemist Bio provides cell treatment to cancer patients. | $7.6M | Seed | Dec 21, 2023 |  |
| Kither Biotech | Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule. | $20.4M | Series B | Mar 16, 2022 |  |

2 of 2 investments shown.

## Co-investors
- [Claris Ventures](https://shizune.co/investors/profile/claris-ventures) — VC Fund, 3 deals together
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund, 2 deals together
- [Italian Angels for Growth](https://shizune.co/investors/profile/italian-angels-for-growth) — VC Fund, 2 deals together
- [2invest](https://shizune.co/investors/profile/2invest-f4d3) — VC Fund, 1 deal together
- [Ace Ventures](https://shizune.co/investors/profile/ace-ventures) — VC Fund, 1 deal together
- Alef 6 — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Ersel invest in?

Ersel invests primarily in Biopharma, Life Science and Therapeutics startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ersel last invest?

The most recent investment recorded for Ersel closed in Dec 2023. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co